Integrated Proteomic Profiling of Cell Line Conditioned Media and Pancreatic Juice for the Identification of Pancreatic Cancer Biomarkers
暂无分享,去创建一个
C. Pilarsky | R. Grützmann | E. Diamandis | S. Gallinger | Yingye Zheng | F. Rückert | I. Batruch | Chris R. Smith | S. Makawita
[1] D. Gill,et al. A MICRO-BIURET METHOD FOR ESTIMATING PROTEINS. , 1964, Analytical biochemistry.
[2] J. Holland,et al. Elevated serum ribonuclease in patients with pancreatic cancer. , 1976, Proceedings of the National Academy of Sciences of the United States of America.
[3] J. Sedmak,et al. A rapid, sensitive, and versatile assay for protein using Coomassie brilliant blue G250. , 1977, Analytical biochemistry.
[4] T. Adrian,et al. Plasma trypsin in chronic pancreatitis and pancreatic adenocarcinoma. , 1979, Clinica chimica acta; international journal of clinical chemistry.
[5] J. Artigas,et al. Serum trypsin levels in acute pancreatic and non-pancreatic abdominal conditions. , 1981, Postgraduate medical journal.
[6] W. Junge,et al. Detection of colipase in serum and urine of pancreatitis patients. , 1982, Clinica chimica acta; international journal of clinical chemistry.
[7] H. Koprowski,et al. Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. , 1983, Cancer research.
[8] E. Engvall,et al. Type VI Collagen: Studies on Its Localization, Structure, and Biosynthetic Form with Monoclonal Antibodies , 1984, The Journal of biological chemistry.
[9] R. Timpl. Type VI Collagen , 1987 .
[10] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[11] O. Itkonen,et al. Time-resolved immunofluorometric assays for trypsinogen-1 and 2 in serum reveal preferential elevation of trypsinogen-2 in pancreatitis. , 1990, The Journal of laboratory and clinical medicine.
[12] Tetsuhide Ito,et al. Clinical Usefulness of Serum Phospholipase A2 Determination in Patients with Pancreatic Diseases , 1991, Pancreas.
[13] T. Hayakawa,et al. Serum pancreatic stone protein in pancreatic diseases , 1993, International journal of pancreatology : official journal of the International Association of Pancreatology.
[14] M. Tsao,et al. Long-term culture and immortalization of epithelial cells from normal adult human pancreatic ducts transfected by the E6E7 gene of human papilloma virus 16. , 1996, The American journal of pathology.
[15] F. Real,et al. The plasminogen activator system in pancreas cancer: role of t-PA in the invasive potential in vitro , 1998, Oncogene.
[16] J. Minna,et al. Comparison of features of human breast cancer cell lines and their corresponding tumors. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[17] F. Aberger,et al. Anterior specification of embryonic ectoderm: the role of the Xenopus cement gland-specific gene XAG-2 , 1998, Mechanisms of Development.
[18] J. Minna,et al. Comparison of features of human lung cancer cell lines and their corresponding tumors. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[19] R. Schmid,et al. Acinar‐Ductal‐Carcinoma Sequence in Transforming Growth Factor‐α Transgenic Mice , 1999 .
[20] R. Schmid,et al. Acinar-ductal-carcinoma sequence in transforming growth factor-alpha transgenic mice. , 1999, Annals of the New York Academy of Sciences.
[21] A. Bozdağ,et al. The diagnostic importance of CEA and CA 19-9 for the early diagnosis of pancreatic carcinoma. , 2000, Hepato-gastroenterology.
[22] 中尾 光輝,et al. KEGG(Kyoto Encyclopedia of Genes and Genomes)〔和文〕 (特集 ゲノム医学の現在と未来--基礎と臨床) -- (データベース) , 2000 .
[23] J. Ringel,et al. The MUC gene family: Their role in diagnosis and early detection of pancreatic cancer , 2003, Molecular Cancer.
[24] W. Antonin,et al. Loss of the Zymogen Granule Protein Syncollin Affects Pancreatic Protein Synthesis and Transport but Not Secretion , 2002, Molecular and Cellular Biology.
[25] A. van Dalen,et al. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin‐2 receptor α levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma , 2002, Cancer.
[26] K. Lillemoe,et al. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. , 2002, Cancer research.
[27] R. Schmid. Acinar-to-ductal metaplasia in pancreatic cancer development. , 2002, The Journal of clinical investigation.
[28] A. Oyarzábal,et al. Marcadores tumorales y reactantes de fase aguda en el diagnóstico del cáncer de páncreas , 2003 .
[29] A. I. Irigoyen Oyarzabal,et al. [Tumoral markers and acute-phase reactants in the diagnosis of pancreatic cancer]. , 2003, Gastroenterology & hepatology.
[30] M. Löhr,et al. A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform , 2003, Virchows Archiv.
[31] L. Wagner,et al. 21. UniGene: A Unified View of the Transcriptome , 2003 .
[32] J. Welsh,et al. Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[33] K. Kinzler,et al. Serum Macrophage Inhibitory Cytokine 1 as a Marker of Pancreatic and Other Periampullary Cancers , 2004, Clinical Cancer Research.
[34] J. Yates,et al. A model for random sampling and estimation of relative protein abundance in shotgun proteomics. , 2004, Analytical chemistry.
[35] Troels Z. Kristiansen,et al. Comprehensive proteomic analysis of human pancreatic juice. , 2004, Journal of proteome research.
[36] Y. Hao,et al. Determination of plasma glycoprotein 2 levels in patients with pancreatic disease. , 2004, Archives of pathology & laboratory medicine.
[37] K. Bushby,et al. Collagen VI related muscle disorders , 2005, Journal of Medical Genetics.
[38] K. Partanen,et al. Tumour-associated trypsin inhibitor in the diagnosis of pancreatic carcinoma , 2005, Journal of Cancer Research and Clinical Oncology.
[39] M. Sadar,et al. Cell lines used in prostate cancer research: a compendium of old and new lines--part 1. , 2005, The Journal of urology.
[40] Gilbert S Omenn,et al. An evaluation, comparison, and accurate benchmarking of several publicly available MS/MS search algorithms: Sensitivity and specificity analysis , 2005, Proteomics.
[41] A. Grapin-Botton. Ductal cells of the pancreas. , 2005, The international journal of biochemistry & cell biology.
[42] S. Regnér,et al. Active Carboxypeptidase B Is Present in Free Form in Serum from Patients with Acute Pancreatitis , 2005, Pancreatology.
[43] M. Mann,et al. Exponentially Modified Protein Abundance Index (emPAI) for Estimation of Absolute Protein Amount in Proteomics by the Number of Sequenced Peptides per Protein*S , 2005, Molecular & Cellular Proteomics.
[44] Gilles Caraux,et al. PermutMatrix: a graphical environment to arrange gene expression profiles in optimal linear order , 2005, Bioinform..
[45] A. Scarpa,et al. Identification of proteins released by pancreatic cancer cells by multidimensional protein identification technology: a strategy for identification of novel cancer markers , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[46] Ilan Beer,et al. Evaluation of prefractionation methods as a preparatory step for multidimensional based chromatography of serum proteins , 2005, Proteomics.
[47] Eugene Kolker,et al. Randomized sequence databases for tandem mass spectrometry peptide and protein identification. , 2005, Omics : a journal of integrative biology.
[48] Ross C. Smith,et al. SHOULD SERUM PANCREATIC LIPASE REPLACE SERUM AMYLASE AS A BIOMARKER OF ACUTE PANCREATITIS? , 2005, ANZ journal of surgery.
[49] Troels Z. Kristiansen,et al. Biomarker Discovery from Pancreatic Cancer Secretome Using a Differential Proteomic Approach*S , 2006, Molecular & Cellular Proteomics.
[50] D. Chan,et al. Serum Markers in Patients with Resectable Pancreatic Adenocarcinoma: Macrophage Inhibitory Cytokine 1 versus CA19-9 , 2006, Clinical Cancer Research.
[51] D. Goldenberg,et al. New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] R. Aebersold,et al. Quantitative proteomic profiling of pancreatic cancer juice , 2006, Proteomics.
[53] Ruedi Aebersold,et al. Challenges and Opportunities in Proteomics Data Analysis* , 2006, Molecular & Cellular Proteomics.
[54] Steven A Carr,et al. Protein biomarker discovery and validation: the long and uncertain path to clinical utility , 2006, Nature Biotechnology.
[55] E. Diamandis,et al. Characterization of Human Kallikreins 6 and 10 in Ascites Fluid from Ovarian Cancer Patients , 2006, Tumor Biology.
[56] A. Lokshin,et al. Multiple biomarker panels for early detection of ovarian cancer. , 2006, Future oncology.
[57] N. Tsuji,et al. Olfactomedin 4 promotes S‐phase transition in proliferation of pancreatic cancer cells , 2007, Cancer science.
[58] E. Diamandis,et al. Proteomics Analysis of Conditioned Media from Three Breast Cancer Cell Lines , 2007, Molecular & Cellular Proteomics.
[59] E. Diamandis,et al. Distribution of 15 human kallikreins in tissues and biological fluids. , 2007, Clinical chemistry.
[60] K. Faber,et al. Comparative proteomic analysis of human pancreatic juice: Methodological study , 2007, Proteomics.
[61] Jiang Qian,et al. TiGER: A database for tissue-specific gene expression and regulation , 2008, BMC Bioinformatics.
[62] I. Petersen,et al. Expression of AGR2 in non small cell lung cancer. , 2007, Histology and histopathology.
[63] Steven P Gygi,et al. Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry , 2007, Nature Methods.
[64] E. Marcotte,et al. Absolute protein expression profiling estimates the relative contributions of transcriptional and translational regulation , 2007, Nature Biotechnology.
[65] Jean-François Hocquette,et al. Assessment of hierarchical clustering methodologies for proteomic data mining. , 2007, Journal of proteome research.
[66] A. Siriwardena,et al. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. , 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[67] D. Gouma,et al. Evaluation of Matrix Metalloproteinase 7 in Plasma and Pancreatic Juice as a Biomarker for Pancreatic Cancer , 2007, Cancer Epidemiology Biomarkers & Prevention.
[68] H. Kato,et al. Plasma proteomics of pancreatic cancer patients by multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis (2D-DIGE): Up-regulation of leucine-rich alpha-2-glycoprotein in pancreatic cancer , 2007, Journal of Chromatography B.
[69] S. Satomura,et al. Serum carboxypeptidase A activity as a biomarker for early-stage pancreatic carcinoma. , 2007, Clinica chimica acta; international journal of clinical chemistry.
[70] R. Aebersold,et al. Comparison of Pancreas Juice Proteins from Cancer Versus Pancreatitis Using Quantitative Proteomic Analysis , 2007, Pancreas.
[71] T. Hayakawa,et al. Enzyme immunoassay for serum pancreatic lipase in the diagnosis of pancreatic diseases , 1989, Gastroenterologia Japonica.
[72] P. Rudland,et al. Increased expression of anterior gradient-2 is significantly associated with poor survival of prostate cancer patients , 2007, Prostate Cancer and Prostatic Diseases.
[73] C. Lindskog,et al. A Web-based Tool for in Silico Biomarker Discovery Based on Tissue-specific Protein Profiles in Normal and Cancer Tissues*S , 2008, Molecular & Cellular Proteomics.
[74] Hyungwon Choi,et al. False discovery rates and related statistical concepts in mass spectrometry-based proteomics. , 2008, Journal of proteome research.
[75] F. Pontén,et al. The Human Protein Atlas—a tool for pathology , 2008, The Journal of pathology.
[76] M. Maeda,et al. Secretion of N-ERC/mesothelin and expression of C-ERC/mesothelin in human pancreatic ductal carcinoma. , 2008, Oncology reports.
[77] J. Lloreta,et al. Murine embryonic stem cell-derived pancreatic acinar cells recapitulate features of early pancreatic differentiation. , 2008, Gastroenterology.
[78] D. Tabb,et al. Evaluation of strong cation exchange versus isoelectric focusing of peptides for multidimensional liquid chromatography-tandem mass spectrometry. , 2008, Journal of proteome research.
[79] Jinxiang Han,et al. Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients , 2008, BMC Cancer.
[80] Huamin Wang,et al. Anterior gradient 2 is expressed and secreted during the development of pancreatic cancer and promotes cancer cell survival. , 2008, Cancer research.
[81] E. Diamandis,et al. Tissue culture‐based breast cancer biomarker discovery platform , 2008, International journal of cancer.
[82] T. Bonaldi,et al. Quantitative proteomics as a new piece of the systems biology puzzle. , 2008, Journal of proteomics.
[83] S. Batra,et al. Early diagnosis of pancreatic cancer: neutrophil gelatinase-associated lipocalin as a marker of pancreatic intraepithelial neoplasia , 2008, British Journal of Cancer.
[84] C. Rubie,et al. Enhanced ENA-78 and IL-8 Expression in Patients with Malignant Pancreatic Diseases , 2008, Pancreatology.
[85] Michelle A. Anderson,et al. A Mouse to Human Search for Plasma Proteome Changes Associated with Pancreatic Tumor Development , 2008, PLoS medicine.
[86] R. Hruban,et al. Pancreatic cancer. , 2021, Annual review of pathology.
[87] Predrag Radivojac,et al. HIP2: An online database of human plasma proteins from healthy individuals , 2008, BMC Medical Genomics.
[88] M. Lerner,et al. Biomarker Identification in Human Pancreatic Cancer Sera , 2008, Pancreas.
[89] E. Diamandis,et al. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies , 2008, Nature Clinical Practice Oncology.
[90] S. Marie,et al. Identification of COL6A1 as a differentially expressed gene in human astrocytomas. , 2008, Genetics and molecular research : GMR.
[91] G. Parmigiani,et al. Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.
[92] C. Stephan,et al. Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers. , 2008, Journal of proteome research.
[93] T. Colgan,et al. Absolute quantification of potential cancer markers in clinical tissue homogenates using multiple reaction monitoring on a hybrid triple quadrupole/linear ion trap tandem mass spectrometer. , 2009, Analytical chemistry.
[94] P. Lescuyer,et al. Proteomic analysis of human bile from malignant biliary stenosis induced by pancreatic cancer. , 2009, Journal of proteome research.
[95] S. Hanash,et al. A Compendium of Potential Biomarkers of Pancreatic Cancer , 2009, PLoS medicine.
[96] J. Winstanley,et al. The metastasis-associated anterior gradient 2 protein is correlated with poor survival of breast cancer patients. , 2009, The American journal of pathology.
[97] Markus Müller,et al. Bioinformatics for protein biomarker panel classification: what is needed to bring biomarker panels into in vitro diagnostics? , 2009, Expert review of proteomics.
[98] Kazuhiro Yoshida,et al. Serum olfactomedin 4 (GW112, hGC‐1) in combination with Reg IV is a highly sensitive biomarker for gastric cancer patients , 2009, International journal of cancer.
[99] B. Nelson,et al. Elevated level of anterior gradient-2 in pancreatic juice from patients with pre-malignant pancreatic neoplasia , 2010, Molecular Cancer.
[100] E. Diamandis,et al. Identification of Five Candidate Lung Cancer Biomarkers by Proteomics Analysis of Conditioned Media of Four Lung Cancer Cell Lines* , 2009, Molecular & Cellular Proteomics.
[101] F. Roviello,et al. CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions. , 2009, American journal of surgery.
[102] E. Diamandis,et al. Comprehensive analysis of conditioned media from ovarian cancer cell lines identifies novel candidate markers of epithelial ovarian cancer. , 2009, Journal of proteome research.
[103] A. Papalambros,et al. CEA and CA-19.9 Serum Tumor Markers as Prognostic Factors in Patients with Locally Advanced (Unresectable) or Metastatic Pancreatic Adenocarcinoma: A Retrospective Analysis , 2009, Journal of chemotherapy.
[104] Jinping Li,et al. HE4 as a biomarker for ovarian and endometrial cancer management , 2009, Expert review of molecular diagnostics.
[105] C. Pilarsky,et al. Functional analysis of LOXL2 in pancreatic carcinoma , 2010, International Journal of Colorectal Disease.
[106] A. Jemal,et al. Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.
[107] Bhavinkumar B. Patel,et al. Proteomic Analyses of Pancreatic Cyst Fluids , 2009, Pancreas.
[108] Jeffrey W. Smith,et al. Mass Spectrometry-Based Label-Free Quantitative Proteomics , 2009, Journal of biomedicine & biotechnology.
[109] M. Neagu,et al. Advances in pancreatic cancer detection. , 2010, Advances in clinical chemistry.
[110] Zhuchu Chen,et al. Identification of biomarkers for predicting nasopharyngeal carcinoma response to radiotherapy by proteomics. , 2010, Cancer research.
[111] D. Tai,et al. Candidate Serological Biomarkers for Cancer Identified from the Secretomes of 23 Cancer Cell Lines and the Human Protein Atlas* , 2010, Molecular & Cellular Proteomics.
[112] R. Dean,et al. Direct comparison of stable isotope labeling by amino acids in cell culture and spectral counting for quantitative proteomics. , 2010, Analytical chemistry.
[113] L. Tanoue. Cancer Statistics, 2009 , 2010 .
[114] M. Büchler,et al. Soluble iC3b as an Early Marker for Pancreatic Adenocarcinoma Is Superior to CA19.9 and Radiology , 2010, Journal of immunotherapy.
[115] M. Gonen,et al. Pancreatic Cyst Fluid and Serum Mucin Levels Predict Dysplasia in Intraductal Papillary Mucinous Neoplasms of the Pancreas , 2010, Annals of Surgical Oncology.
[116] M. Girolami,et al. Recommendations for Biomarker Identification and Qualification in Clinical Proteomics , 2010, Science Translational Medicine.
[117] Maria P. Pavlou,et al. Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer , 2010, Nature Reviews Cancer.
[118] M. Lai,et al. Identification of serum biomarkers for colorectal cancer metastasis using a differential secretome approach. , 2010, Journal of proteome research.
[119] L. Foster,et al. Quantitative analysis of proteome coverage and recovery rates for upstream fractionation methods in proteomics. , 2010, Journal of proteome research.
[120] T. Veenstra,et al. Comparison of strong cation exchange and SDS-PAGE fractionation for analysis of multiprotein complexes. , 2010, Journal of proteome research.
[121] M. Nowak,et al. Distant Metastasis Occurs Late during the Genetic Evolution of Pancreatic Cancer , 2010, Nature.
[122] C. Pilarsky,et al. Serum Tumor Markers in Pancreatic Cancer—Recent Discoveries , 2010, Cancers.
[123] Chi Zhang,et al. TiSGeD: a database for tissue-specific genes , 2010, Bioinform..
[124] J. Shea,et al. Phenotype and Genotype of Pancreatic Cancer Cell Lines , 2010, Pancreas.
[125] P. Allavena,et al. Secretome analysis of multiple pancreatic cancer cell lines reveals perturbations of key functional networks. , 2010, Journal of proteome research.
[126] S. Hanash,et al. The grand challenge to decipher the cancer proteome , 2010, Nature Reviews Cancer.
[127] Susumu Goto,et al. KEGG for representation and analysis of molecular networks involving diseases and drugs , 2009, Nucleic Acids Res..
[128] A. Passaniti,et al. ErbB3 binding protein 1 represses metastasis-promoting gene anterior gradient protein 2 in prostate cancer. , 2010, Cancer research.
[129] Rosalind J. Cutts,et al. The Pancreatic Expression database: 2011 update , 2010, Nucleic Acids Res..